DDW-2019-postevent

 

App Store google-play

Read the full abstract from our Challenges and Controversies in Barrett’s Esophagus podium presentation from DDW
See our Press Release on the Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining
Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus

Barrett's Esophagus & Esophageal Cancer

Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
News
View All News
07/1/2019
Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease... Read More
05/8/2019
Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019... Read More
11/20/2018
Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics... Read More
Events
01/09/2017 — San Francisco, CA
JP Morgan Healthcare Conference
05/06/2017 — Chicago, IL
Digestive Disease Week
10/13/2017 — Orlando, FL
American College of Gastroenterology
Customer Service

Mon-Fri 9am-5pm (EST)

Email 412-820-3050
×